Activation of blood platelets by thrombin was previously shown to specifically release protein kinase A, which in human plasma singles out and phosphorylates one protein, identified as vitronectin. This protein is known to be involved in processes that follow platelet stimulation, specifically, in the binding of heparin (interfering with the heparin-mediated inhibition of thrombin and Factor Xa by antithrombin III), in the growth of endothelial cells and in fibrinolysis. This paper shows that phosphorylation of vitronectin by protein kinase A is stoichiometric (approx. 1 mol/mol), that it is targeted to one site (Ser-378) at the C-terminal edge of the heparin-binding domain, and that it distinguishes between the two physiologically occurring forms of vitronectin: the one-chain (75 kDa) form, and the nicked two-chain (65 + 10 kDa) form, held together by an interchain disulphide bridge. Protein kinase A phosphorylates the one-chain form but not the two-chain form, although Ser-378 and the complete recognition sequence of the kinase are still present in the clipped 65 kDa chain. Cleavage of the Arg-379-Ala-380 bond results therefore in a conformationally distinct form of vitronectin in which Ser-378 is 'buried'. This is demonstrated by our finding that Ser-378 is present in the 65 kDa chain of clipped vitronectin but inaccessible to phosphorylation at physiological pH. Upon binding heparin, the phosphorylation site becomes exposed and able to undergo a stoichiometric phosphorylation at physiological pH.
INTRODUCTION
The concerted phosphorylation of proteins by cyclic AMPdependent protein kinase (PKA) plays a key role in the intracellular implementation of hormonal stimuli mediated by the second messenger cyclic AMP (Sutherland & Rall, 1960; Walsh et al., 1968; Cohen, 1988) . We have recently provided evidence suggesting that, in addition to its well-established functions within the cell, PKA may also have physiological extracellular functions (Korc-Grodzicki et al., 1988a,b) . This was based on our finding that, upon stimulation of rabbit platelets with thrombin (one of their physiological agonists), they specifically release PKA (along with its co-substrate ATP), which selectively phosphorylates one plasma protein (Korc-Grodzicki et al., 1988a ). Subsequently we showed that human platelets similarly release PKA upon thrombin stimulation, and that in this case also PKA singles out and phosphorylates one of the numerous proteins in human plasma. The protein specifically phosphorylated in human plasma was immunochemically and biochemically identified as vitronectin (Korc-Grodzicki et al., 1988b) .
Vitronectin (also known as S-protein, serum spreading factor and epibolin) is a rather abundant glycoprotein in human plasma and serum (100-500 ,ug/ml) (Podack & Miiller-Eberhard, 1979; Hayman et al., 1983; Shaffer et al., 1984) . It promotes cell adhesion and spreading Hayman et al., 1985; Silnutzer & Barnes, 1985; Yatohgo et al., 1988) , binds to activated platelets (Thiagarajan & Kelly, 1988) and binds to endothelial cells in suspension (Preissner et al., 1988) . These processes can be inhibited by peptides containing an Arg-Gly-Asp sequence, suggesting that the binding takes place through integrin cell receptors for vitronectin (Pytela et al., 1986; Suzuki et al., 1987) . In addition, vitronectin has been shown to bind heparin and to interfere with the heparin-mediated inhibition of thrombin and Factor Xa by antithrombin III (Preissner et al., 1985; Preissner & MullerBerghaus, 1986 , 1987 Podack et al., 1986) and to inhibit the lytic activities of complement factors C7, C8 and C9 (Podack et al., 1977 (Podack et al., , 1984 Preissner et al., 1983) .
At least in vitro, vitronectin appears to be secreted (from cultured HepG2 cells) as an intact single-chain polypeptide with an apparent molecular mass of about 75 kDa (Suzuki et al., 1985; Jenne & Stanley, 1987) , but in circulating plasma vitronectin exists in two forms, a single-chain polypeptide (V75) and a nicked polypeptide (V65+10) in which the two chains are linked by an interchain disulphide bond Dahlback & Podack, 1985) . The cleavage site for the conversion of the V7. into the V65+10appears to be between Arg-379 and Ala-380, which immediately follows the C-terminus of the heparin-binding domain (positions 341-379) (Suzuki et al., 1984; Jenne & Stanley, 1985) .
Since vitronectin and thrombin are implicated in both the haemostatic process and the modulation of complement function (Machovich, 1984; Preissner, 1989) 
Vitronectin
Vitronectin was prepared from freshly frozen human plasma using a purification procedure described elsewhere (KorcGrodzicki et al., 1990) . Our preparations usually contained the two molecular forms of this protein: V75, a one-chain (75 kDa) form, and V65+10, a proteolytically clipped two-chain protein (65 kDa and 10 kDa) held together by a disulphide bridge (Dahlback & Podack, 1985; Jenne & Stanley, 1985) . These two forms of vitronectin were partially resolved on Blue Sepharose with a shallow salt gradient (0.15-1 M-NaCl). In this preparation (not shown) the bulk of vitronectin emerged from the column as a broad peak containing V75 and V65+10 that was preceded by some fractions containing mainly V65+10 and followed by some fractions containing essentially pure V75.
Catalytic subunit of PKA Pure catalytic subunit of PKA was prepared by the method of Beavo et al. (1974) and assayed as described by Kupfer et al. (1979) . The resulting enzyme preparations had a specific activity of 8-13 units/mg. One unit of enzyme activity is defined as the amount of enzyme that catalyses the transfer of 1 umol of [32P]phosphate from [y-32P]ATP to histone H2B/min at pH 6.5 and 30°C (Jimenez et al., 1982 Bradford (1976) . SDS/PAGE was carried out according to the procedure described by Laemmli (1970) (Fling & Gregerson, 1986) (Matsudaira, 1987) 
RESULTS

PKA differentiates between the intact form and the nicked form of vitronectin
When purified human vitronectin is subjected to SDS/ PAGE(R), then stained with Coomassie Blue or immunoblotted with rabbit anti-(human vitronectin) antibody, it appears as two protein bands (75 kDa and 65 kDa; Fig. 1 , lanes A and B) (cf. also Dahlback & Podack, 1985) . However, only the 75 kDa band becomes phosphorylated when the preparation is incubated with the C subunit of PKA and [y-32P]ATP (Fig. 1, lane C) . The 75 kDa band seen in SDS/PAGE(R) represents the native (one-chain) vitronectin (V75) (Scheme 1), and the 65 kDa band is derived from an endogenous cleavage of the Arg-379-Ala-380 peptide bond at the C-terminal edge of its heparin-binding domain (Dahlback & Podack, 1985; Jenne & Stanley, 1985; Suzuki et al., 1985; Ruoslahti et al., 1987) . This cleavage thus converts V75 into a nicked form V65+10, composed of a 65 kDa chain and a 10 kDa chain that are held together by an interchain disulphide bridge (Scheme 1).
In view of the substrate-recognition properties of PKA (Zetterqvist et al., 1976) , Ser-378 in the sequence Arg-Arg-ProSer-Arg-Ala was tentatively identified as a plausible site for phosphorylation in vitronectin by this enzyme (Korc-Grodzicki , 1988b ). Yet, although the formation of V65+10 should retain this residue in the penultimate position at the C-terminus of the heavy chain (V65), and within a sequence sufficient for recognition by PKA, the phosphorylation of the clipped form of vitronectin does not occur under the standard conditions of our assay, performed at pH 7.5.
PKA phosphorylation site is 'buried' in V65+10
The discriminatory behaviour of PKA in the phosphorylation of V75 but not of V6s+10 (Fig. 1) 'buried' or inaccessible to the kinase. Since Ser-378 is located at the C-terminal end of the heparinbinding domain and since heparin has been shown to induce significant conformational changes in vitronectin (Tomasini & Mosher, 1988; Hildebrand et al., 1988) , we investigated the effect of heparin on the accessibility of this residue to phosphorylation by PKA. As shown in Fig. 2 , heparin (50 ,ug/ml) has a pronounced effect on the phosphorylation of the 65 kDa Co2H V65+,0 + heparin Ser-378 exposed Scheme 1. Representation of the structure and conformation of V75, V65+10 and V65+10 with heparin, under conditions of physiological pH and ionic strength In V75 the positively charged heparin-binding domain (A) and the negatively charged N-terminal domain (B) are held together by electrostatic forces. Note that, in V75, Ser-378 is exposed, but it becomes inaccessible to phosphorylation ('buried') as a result of the endogenous cleavage (between Arg-379 and Ala-380) that converts it into a two-chain form, and that, upon binding of heparin, Ser-378 becomes exposed again and can then be stoichiometrically phosphorylated by PKA. band originating from V65,10 (as is shown below). In V65+10 heparin 'exposes' the phosphorylation site for PKA at physiological pH and makes it as accessible to the kinase as it is at pH 6.0 in the absence of heparin (Fig. 2 , compare lanes G and H with lanes A and B).
In order to establish whether the 65 kDa band observed after SDS/PAGE(R) and shown to undergo a heparin-dependent phosphorylation represents a physiologically relevant Vs5+10 form of vitronectin, we took advantage of a preparation in which the fractions containing the 75 kDa and 65 kDa bands observed in SDS/PAGE(R) were partially resolved during chromatography on Blue Sepharose, as described in the Experimental section (cf. also Dahlback & Podack, 1985) . These fractions were phosphorylated (at pH 7.5) in the absence and in the presence of heparin, and then subjected to SDS/PAGE under reducing or non-reducing conditions. As shown in Fig. 3, D) ; 50 mM-Hepes, pH 7.0 or 7.5 (lanes E-H). Phosphorylation of vitronectin was allowed to proceed (15 min at 30 C) with the catalytic subunit of PKA (2.5 ,UM), [y-32P]ATP (10 /tM; 0.5 Ci/mmol) and magnesium acetate (10 mM) (all final concentrations). The reaction was arrested by addition of sample buffer and boiling (3 min at 95°C). The samples were then subjected to SDS/PAGE(R) (100 0 gels) and autoradiography. (Fling & Gregerson, 1986) . The radioactively labelled fragments were detected by autoradiography. Kemptide (Kemp et al., 1977 ) (Leu-Arg-Arg-Ala-Ser-Leu-Gly), which are commonly used as substrates of PKA. In the presence of heparin the rate of phosphorylation of the protein is reduced approx. 1.6-fold and that of the peptide is reduced approx. 3.6-fold. bin and its use to identify the site of the PKA phosphorylation Vitronectin (2.8,M) was incubated at 37°C with a-thrombin (50 units/ml) in the absence and in the presence ofheparin (50 ,ug/ml) (lanes A and B and lanes C and D respectively, a). Immediately after the addition of z-thrombin (lanes A and C) and after 30 min incubation (lanes B and D) , the samples were boiled in the presence of SDS (2%) and 2-mercaptoethanol (0.75 M). The proteins were analysed by SDS/PAGE(R) (with a linear gradient of 7-20/0 polyacrylamide), fixed and stained as described in the Experimental section. In a similar experimental setting (b) vitronectin was first radiolabelled by phosphorylation at pH 6.0, as described in the legend to Fig. 1 . The material was then extensively dialysed against 50 mM-Hepes buffer, pH 7.5 containing GSH (1 mM) to remove excess [y-32P]ATP. Portions of 32P-labelled vitronectin were subsequently incubated as described above with az-thrombin in the absence and in the presence of heparin (lanes E-G and H-J for 2, 15 and 30 min respectively). The phosphorylated cleavage products were analysed by SDS/PAGE(R) and autoradiography.
IO% gels were used in (a) and 7-20 % gels in (b).
In view of the fact that ionic interactions play a dominant role in the heparin-neutralizing activity of vitronectin (Preissner & Miiller-Berghaus, 1987; Lane et al., 1987) , we were interested to investigate how the ionic strength of the medium may influence the heparin-triggered phosphorylation of vitronectin. As shown in Fig. 5 , NaCl (in the range 0-300 mM) essentially abolishes the heparin-dependent phosphorylation of isolated V65+10at 150 mMNaCl, whereas it only slightly inhibits the phosphorylation of V75.
Identification of Ser-378 as the sole site phosphorylated by PKA Phosphorylation of vitronectin with PKA and [y-32P]ATP (under conditions that bring about stoichiometric phosphorylation of both V75 and V65+10) and subsequent amino acid hydrolysis shows that serine is the only amino acid residue that becomes phosphorylated (Fig. 6a) . Since, in the presence of heparin, only 1 mol of [32P]phosphate is incorporated/mol of both the 75 kDa and the 65 kDa bands, and since no 32P-labelled 10 kDa fragment is detected after reduction of V65+10 with thiols, we conclude that the 65 kDa polypeptide chain still contains all the 32p label, and therefore that the PKA phosphorylation site is not within residues 380 and 459. On the other hand, when the isolated 32P-labelled 65 kDa band is subjected to CNBr cleavage, then to SDS/PAGE(R) and autoradiography, only one phosphorylated (12 kDa) band is finally formed (Fig. 6b) , suggesting that the phosphorylation site resides in one CNBr-cleavage peptide, probably the 12 kDa peptide identified by Suzuki et al. (1984) as the peptide containing the heparin-binding domain in vitronectin (residues 348-379; cf. Ruoslahti et al., 1987) .
Additional information for the identification of the PKA phosphorylation site was obtained by the fragmentation of vitronectin with a-thrombin. As shown in Fig. 7, heparin recognition site (Silnutzer & Barnes, 1984) from both the 75 kDa and the 65 kDa bands of vitronectin (Fig. 6a) . However, when portions of the reaction mixture at different times were subjected to SDS/PAGE(R) and autoradiography, the phosphorylated site was found to reside not in the 58 kDa band but in a previously unidentified 17 kDa band (Fig. 7b) .
The a-thrombin cleavage products were subjected to sequence analysis. As shown in Table 1 , the 58 kDa polypeptide that did not contain the phosphorylation site was found to have an N-terminal sequence identical with that of intact vitronectin (residues 1-4 and 6-7 positively identified). On the other hand, the 17 kDa polypeptide (which contained the radioactive label) had a sequence identical with residues 305-315 (all positively identified). Two other peptides that were not labelled migrated slightly lower on SDS/PAGE than the 17 kDa band shown in Fig. 7 . They were found to have a sequence identical with that of residues 380-385 in vitronectin (numbered in accordance with Jenne & Stanley, 1985) . These two peptides, which migrate together, do not appear to be derived from the thrombin cleavage, and presumably represent the new N-terminus formed as a result of the endogenous cleavage that yields V65+10 from V75. The two sequences were identical apart from the appearance of either threonine or methionine at the second residue position, a singlepoint polymorphism that has been previously reported in sequences obtained from two different cDNA clones of human vitronectin (see Table 1 ).
Taken together, these results would place the site of PKA phosphorylation between positions 306 and 379, which accommodates the heparin-binding domain of vitronectin (Suzuki et al., 1984; Ruoslahti et al., 1987) . Within this region, there is one serine residue in an optimal sequence for phosphorylation by PKA, since two adjacent basic amino acid residues are usually found at positions n -2 and n -3 N-terminal to a serine or threonine residue at a position n for phosphorylation by PKA (Kemp et al., 1977; Feramisco et al., 1980 (Fig. 6b) to trypsin cleavage and showed that a single radioactively labelled peptide was obtained that co-migrated on thin-layer electrophoresis with the tryptic product of the Ser-5-phosphorylated synthetic heptapeptide (Fig. 8) . The tryptic products in both cases (ArgPro-Ser-Arg) correspond to the sequence around vitronectin (positions 376-379).
DISCUSSION
Previously we have shown that PKA is specifically released following thrombin stimulation of platelets (Korc-Grodzicki et al., 1988a,b) . In human plasma, vitronectin was shown to be the sole substrate for PKA and to undergo a phosphorylation that requires Mg2+ (Korc-Grodzicki et al., 1988b , 1990 The interactions between vitronectin and heparin are thought to be primarily ionic (Suzuki et al., 1985; Jenne & Stanley, 1985; Lane et al., 1987 Fig. 5 ) that the phosphorylation of vitronectin by PKA would be limited to V75. It is pertinent to note, however, that heparin binding to vitronectin, which is below maximal in the native structure Preissner & Miiller-Berghaus, 1987) , is enhanced by thrombospondin following platelet activation (Tomasini & Mosher, 1985) and by exposure of vitronectin to the thrombin-antithrombin III complex (Tomasini & Mosher, 1988) . The possible role of these molecules, as well as other plasma (or serum) proteins, in modulating the phosphorylation of vitronectin by PKA requires further investigation.
In the native state, a number of the functional domains of vitronectin that are located in separate well-defined regions of the protein (Suzuki et al., 1984) appear to be 'buried'. These include the heparin-binding site Preissner & Miiller-Berghaus, 1987) , the collagen-binding site (Gebb et al., 1986 ) and the cell-recognition site (Preissner et al., 1988) . Altered conformational states of vitronectin (which have been measured by the expression of an antigenic epitope) have implicated several possible effectors (including heparin and the thrombinantithrombin III complex) in the modulation of cell adhesion, binding of vitronectin to extracellular-matrix collagen and cellsurface constituents such as thrombomodulin (Tomasini & Mosher, 1988; Tomasini et al., 1989; Hildebrand et al., 1989 ).
The exact difference in the physiological assignment of the two circulating forms of vitronectin, V75 and V65+10, has yet to be established. Nonetheless, the results described here demonstrate that there is a marked difference between these two forms of vitronectin, not merely in their binding to heparin (cf. Ill & Ruoslahti, 1985; Izumi et al., 1988) , but also in their specific conformational response to this modulator. The work presented in this paper shows that vitronectin has a single phosphorylation site for PKA and makes use of this specific phosphorylation to probe the conformation of the molecule. This novel approach enabled us to show that V65+10 has a unique functional flexibility, which is illustrated by the lack of phosphorylation by PKA in the absence of heparin, contrasted with a stoichiometric phosphorylation at physiological pH in the presence of heparin.
Although the role of phosphorylation by PKA remains to be established, the identification of Ser-378 as the sole site for PKA action, and the proximity of the phosphorylation site to the point of cleavage that converts V75 into V65 10' focuses attention on a putative role for PKA in the modulation of this cleavage.
Further studies are required to examine the possible relationship between the phosphorylation ofvitronectin by PKA and the endogenous cleavage of the intact molecule into its two-chain form.
